Literature DB >> 17380475

Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study.

Clive Holmes, David Wilkinson, Christine Dean, Corinne Clare, Mohammed El-Okl, Christine Hensford, Sheram Moghul.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17380475     DOI: 10.1002/gps.1667

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


× No keyword cloud information.
  6 in total

Review 1.  Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials.

Authors:  Salvatore Gentile
Journal:  Psychopharmacology (Berl)       Date:  2010-07-27       Impact factor: 4.530

Review 2.  Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review.

Authors:  Emilio Sacchetti; Cesare Turrina; Paolo Valsecchi
Journal:  Drug Saf       Date:  2010-04-01       Impact factor: 5.606

Review 3.  Rivastigmine for Alzheimer's disease.

Authors:  Jacqueline S Birks; Lee Yee Chong; John Grimley Evans
Journal:  Cochrane Database Syst Rev       Date:  2015-09-22

Review 4.  Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia.

Authors:  Viktoria Mühlbauer; Ralph Möhler; Martin N Dichter; Sytse U Zuidema; Sascha Köpke; Hendrika J Luijendijk
Journal:  Cochrane Database Syst Rev       Date:  2021-12-17

5.  Pharmacological treatments for alleviating agitation in dementia: a systematic review and network meta-analysis.

Authors:  Khachen Kongpakwattana; Ratree Sawangjit; Itthipol Tawankanjanachot; J Simon Bell; Sarah N Hilmer; Nathorn Chaiyakunapruk
Journal:  Br J Clin Pharmacol       Date:  2018-05-14       Impact factor: 4.335

Review 6.  Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review.

Authors:  Dallas P Seitz; Sudeep S Gill; Nathan Herrmann; Sarah Brisbin; Mark J Rapoport; Jenna Rines; Kimberley Wilson; Ken Le Clair; David K Conn
Journal:  Int Psychogeriatr       Date:  2012-10-19       Impact factor: 3.878

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.